teensexonline.com
Search
Global Markets

Avrobio Offloads Genetics Treatment Program For Rare Congenital Disease To Novartis

By: Financial News Buzz

Date:

 

  • Avrobio Inc ( NASDAQ: AVRO) concurred to market its investigational hematopoietic stem cell (HSC) genetics treatment program for cystinosis to  Novartis AG ( NYSE: NVS) for $ 87.5 million in cash money. 
  • Cystinosis is identified by the buildup of the amino acid cystine (a foundation of healthy proteins) within cells. Excess cystine problems cells and also commonly …

Complete tale offered on Benzinga.com

Previous article
Cathie Timber’s Suggestions on Exactly how to Master Your Work following AI
Next article
Nvidia ETFs Look Solid Ahead of Q1 Incomes
Financial News Buzz
Financial News Buzz

Share post:

Subscribe

Popular

More like this
Related

About us

Financial News Buzz is an independent news site that focuses on everything from mainstream news stories to pop culture and varying opinions. While providing coverage and analysis of daily headlines and big stories of the day, Financial News Buzz also offers insightful political commentary and informed perspectives

Company

The latest

Subscribe

Disclaimer: The content provided is for informational purposes only. We aim to keep the content current and accurate by updating it frequently. Sometimes the actual data can differ from what's stated on our website. Financialnewsbuzz.com is an independent platform. While we are independent, we may be compensated for advertisements, sponsored products, or when you click on a link on our website. The contributors and authors are not registered or certified financial advisors. You should consult a financial professional before making any financial decisions.

Copyright © Financial Buzz News